100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study

C. Palmieri,H. Linden,S. Birrell,E. Lim,L.S. Schwartzberg, H.S. Rugo,P. Cobb, K. Jain,C. Vogel, J. O'Shaughnessy, S.R.D. Johnston, R.H. Getzenberg,K.G. Barnette,M. Steiner, A.M. Brufsky, B. Overmoyer

Annals of Oncology(2021)

引用 0|浏览1
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要